ASC-618

N/A

Report date: 2023/10/26 17:04:32

Base Information

Drug NameASC-618

Drug Alias NameRecombinant adeno-associated virus serotype 8 (rAAV2/8) vector expressing bioengineered B domain deleted liver-codon-optimized human factor VIII(ASC Therapeutics)ASC-618

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/8 vector

Mechanisms of ActionGene transferenceFactor VIII gene transference

TargetsCoagulation factor VIII

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesInvasc Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesASC Therapeutics

Inactive CompaniesN/A

Active IndicationsHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeN/A